Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147435 | 0.81 | HRH3 (0.60) | ALDH1A1KMT2AGFERHRH3SIGMAR1 | |
| SCHEMBL9995252 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KMT2AGFERHRH3LTA4H | |
| SCHEMBL3278961 | 0.77 | ALOX5 (0.51) | ALDH1A1KMT2AKDM4EHPGDTSHR | |
| SCHEMBL5758121 | 0.77 | ADRA2C (0.61) | ALDH1A1KMT2AGFERPOLBKDM4E | |
| SCHEMBL5356971 | 0.73 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERPOLBHPGD | |
| SCHEMBL10107784 | 0.73 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERPOLBHPGD | |
| SCHEMBL5753660 | 0.73 | SIGMAR1 (0.57) | ALDH1A1KDM4ESIGMAR1TSHR | |
| Hydrochloric Acid SCHEMBL29354698 | 0.72 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERPOLBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL10675086 | 0.72 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERPOLBSIGMAR1 | |
| SCHEMBL7203830 | 0.72 | ALOX5 (0.47) | ALDH1A1KMT2AKDM4EHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030009030-A1 | Novel selective deacetylating agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1245550-A1 | NOVEL SELECTIVE DEACETYLATING AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009030-A1 | Novel selective deacetylating agents | HDAC1, HDAC11, HDAC3 | ALDH1A1 1010/4885KMT2A 106/4885GFER 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.